{"id":118882,"date":"2021-07-27T09:43:12","date_gmt":"2021-07-27T09:43:12","guid":{"rendered":"https:\/\/www.edristi.in\/?p=118882"},"modified":"2021-07-27T09:43:13","modified_gmt":"2021-07-27T09:43:13","slug":"license-agreement-for-covid-19-drug-2-dg","status":"publish","type":"post","link":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/license-agreement-for-covid-19-drug-2-dg\/","title":{"rendered":"License agreement for COVID-19 drug 2-DG"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Question : Which pharma company has recently(July 2021) inked license agreement with DRDE &amp; INMAS to produce,distribute &amp; market COVID-19 drug 2-DG ?<br><\/strong>a. Glenmark Pharma<br>b. Sun Pharma<br>c. BDR Pharma<br>d. Cadila<br><strong>Ans. c.<br>Related facts &#8212;<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>BDR Pharma has recently(July 2021) inked a pact with the Defence Research and Development Establishment (DRDE) and the Institute of Nuclear Medicine and Allied Sciences (INMAS) of the DRDO for manufacturing, distribution, and marketing of 2-DG in the country.<\/li><li>It is notable that last month, the Drugs Controller General of India (DCGI) had approved the oral medication for emergency usage as adjuvant therapy in mild to severe COVID-19 patients.<\/li><li>BDR Pharma has already applied to the Drug Controller General of India (DCGI) for restricted emergency use authorisation to manufacture Drug 2-DG to treat COVID-19 patients in India.<\/li><li>COVID-19 drug 2-Deoxy-D-Glucose (2-DG) would be priced competitively and will be available in powder form in a sachet that can be consumed orally after being dissolved in water.<\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>DRDE &#8212;<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Defence Research &amp; Development Establishment is an Indian defence laboratory of the Defence Research and Development Organisation.<\/li><li>Located in Gwalior, it is primarily involved in the research and development of detection and protection against toxic chemical and biological agents.<\/li><\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>INMAS &#8212;<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>Institute of Nuclear Medicine &amp; Allied Sciences is a laboratory of the Defence Research and Development Organisation.<\/li><li>Located in Timarpur, Delhi, it is involved in Nuclear medicine research and responding to nuclear accidents and explosions.<\/li><\/ul>\n\n\n\n<p class=\"has-text-align-right wp-block-paragraph\"><strong>By &#8212; Pankaj Pandey.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Link:<\/strong><br><a href=\"https:\/\/economictimes.indiatimes.com\/industry\/healthcare\/biotech\/pharmaceuticals\/bdr-pharma-inks-license-agreement-with-drdo-to-produce-covid-19-drug-2-dg\/articleshow\/84753067.cms\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/economictimes.indiatimes.com\/industry\/healthcare\/biotech\/pharmaceuticals\/bdr-pharma-inks-license-agreement-with-drdo-to-produce-covid-19-drug-2-dg\/articleshow\/84753067.cms<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Question : Which pharma company has recently(July 2021) inked license agreement with DRDE &amp; INMAS to produce,distribute &amp; market COVID-19 drug 2-DG ?a. Glenmark Pharmab. Sun Pharmac. BDR Pharmad. CadilaAns. c.Related facts &#8212; BDR Pharma has recently(July 2021) inked a pact with the Defence Research and Development Establishment (DRDE) and the Institute of Nuclear Medicine [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":118883,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1151],"tags":[],"class_list":["post-118882","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tta"],"_links":{"self":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts\/118882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/comments?post=118882"}],"version-history":[{"count":1,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts\/118882\/revisions"}],"predecessor-version":[{"id":118884,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts\/118882\/revisions\/118884"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/media\/118883"}],"wp:attachment":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/media?parent=118882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/categories?post=118882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/tags?post=118882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}